Skip to main content
ZLDAF logo

Zelira Therapeutics Limited (ZLDAF) Stock Price & Analysis

Zelira Therapeutics Limited (ZLDAF) — price $0.2045 (0.00%), as of the Nov 19, 2026 trading session; market cap $2.69M.

Educational signal · not a buy or sell recommendation · How to read this

$0.2045 $0.00 (0.00%) Market Cap $2.69M

Zelira Therapeutics Limited · ZLDAF

Zelira Therapeutics Limited (ZLDAF) is an Australian biopharmaceutical company focused on cannabinoid-derived therapeutic agents for various medical conditions. The company is actively developing its product pipeline, including cannabinoid-based medicines for chronic insomnia and other health issues.

Price as of Nov 19, 2026

Key Statistics

Not scored: MoonshotScore covers actively traded US operating companies, not funds, preferred shares, warrants or thinly traded stocks.

Thousands of the 20,000+ US stocks here carry a MoonshotScore.

Scored companies in the same industry:

  • CRON · Cronos Group Inc. · 95 /100
  • CGC · Canopy Growth Corporation · 16 /100
  • TLRY · Tilray Brands, Inc. · 20 /100

See all scored stocks →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$0.2045
Change on the day0.00%
52-week range$0.0089 – $0.4165
Market capitalisation$2.69M
Shares traded on the day571

Price & events

Other perspectives

Council score for Zelira Therapeutics (ZLDAF): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Legends Council

4 lenses, 0 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Englander-style lens (simulated) Izzy Englander Favorable read
Klarman-style lens (simulated) Seth Klarman Unfavorable read
Moon AI lens (model) Neutral read

Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Weak
Margin of Safety Fairly Valued
Profit Margin Weak
Revenue Growth Negative
Debt/Equity Strong
ROE Strong
Gross Margin Negative

Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Sep 10, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is Zelira Therapeutics (ZLDAF), and what does it report?

Short answer · as of

A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Zelira Therapeutics Limited (ZLDAF) is the company analyzed here. It employs 8 people and is led by Oludare Odumosu. In Q4 FY2025 it reported revenue of A$0.658 and net income of -A$1M. The market values it at $2.69M.

2 · Latest results

What do the latest results show for Zelira Therapeutics (ZLDAF)?

Short answer · as of

The most recent reported quarter, Q4 FY2025, carried revenue of A$0.658.

Quarterly income statement — 3 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Q4 FY2025A$0.658-A$1M-A$0.10 (diluted)
Q2 FY2025A$655-A$2M-A$0.21 (diluted)
Q4 FY2024A$40,229-A$2M-A$0.21 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Zelira Therapeutics (ZLDAF)?

Short answer · as of

The distress and quality screens read Piotroski F 1. Trailing ratios: ROE 80.8% · current ratio 0.11 · earnings yield -63.2% · free-cash-flow yield -74.6%.

The records behind this page

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held ZLDAF in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported ZLDAF in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

Zelira Therapeutics Stock: Key Questions Answered

These answers are editorial: 1 of these 8 answers is drawn from the ZLDAF research dossier (written Jun 14, 2026 by gpt-4o-mini); the other 7 are question templates that restate figures shown above. Figures in this section are not part of the source register.

Is ZLDAF a good stock to buy?

Stock Expert AI does not rate ZLDAF buy, sell or hold. Zelira Therapeutics Limited has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the ZLDAF stock price today?

The last price recorded for Zelira Therapeutics Limited (ZLDAF), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What are the main risks for ZLDAF?

Zelira Therapeutics Limited faces several risks, including regulatory challenges that could impact the cannabis industry and its operations. The company also contends with intense competition from established pharmaceutical firms and market volatility due to its OTC trading status, which may affect liquidity and stock price stability.

What are the key factors to evaluate for ZLDAF?

Evaluate ZLDAF on fundamentals, analyst consensus, and risk factors. No dividend yield as the company is reinvesting earnings into product development and clinical trials. Not financial advice.

How frequently does ZLDAF data refresh on this page?

ZLDAF's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven ZLDAF's recent stock price performance?

Zelira Therapeutics Limited (ZLDAF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative focus on cannabinoid-derived therapeutics. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider ZLDAF overvalued or undervalued right now?

Zelira Therapeutics Limited (ZLDAF) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

How do I research ZLDAF before investing?

Before investing in Zelira Therapeutics Limited (ZLDAF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).

Machine-generated analysis by Stock Expert AI — model gpt-4o-mini, generated Jun 14, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 13 figures on this page — 8 from Financial Modeling Prep (FMP) and 5 with no recorded source. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.